CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 509 enrolled
Drug / intervention
CYP2C19 genotypinggenetic
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02508116
NCT02508116N/ACompleted
CompareCT.gov

Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention (ADAPT)

University of Pennsylvania·interventional·Posted Jul 24, 2015·Updated Nov 7, 2018

In Brief

A clinical study evaluating CYP2C19 genotyping for Acute Coronary Syndrome and Cardiovascular Diseases. Completed, enrolled 509 participants across 2 sites.

Detailed Summary

This is a randomized, prospective, open label study to determine the cost-effectiveness of genotype-guided antiplatelet therapy. Patients undergoing percutaneous intervention (PCI) with stent implantation, will be randomized either to genotype guided dosing of antiplatelet therapy or usual care. The study utilizes a novel genotyping device, SpartanRx, to determine CYP2C19 genotypes from a buccal swab sample with 1 hour turnaround time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Coronary Syndrome, Cardiovascular Diseases
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 24, 2015
Enrollment StartNov 1, 2014
Primary CompletionMay 1, 2017
Study CompletionAug 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.9 years ago

Interventions

CYP2C19 genotypinggenetic

The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 \*2, \*3, and \*17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time